Livatag®

BioAlliance Pharma receives €4.3 million in funding from bpifrance (ex OSEO) to accelerate the industrial development of Livatag® Grant to support NICE: France’s first nanomedicine consortium led by BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to the development of orphan oncology products and supportive care products, today announced funding of almost €9 million from bpifrance through a Strategic Industrial Innovation (ISI) program. An amount of €4.3 million will be allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag®. This grant supports the…read more →

BioAlliance Pharma launches a capital increase of €8 million with maintenance of preferential subscription rights to accelerate the development of the two major orphan products (Livatag® and Validive®)

Issue price: 3.50 € Subscription commitment of €5 million from two reference shareholders (representing 63% of the issue) 1 new share issued for 8 existing shares The subscription period will run from July 2, 2013 to July 12, 2013 on BioAlliance Pharma SA (Euronext Paris – BIO — FR0010095596), an innovative Company dedicated to orphan oncology products and specialty products,…read more →

BioAlliance Pharma announces DSMB second positive recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today announced that the International Independent Board of Experts’ Data and Safety Monitoring Board (DSMB) again recommended continuing the ReLive Phase III trial without modification. The DSMB meets every 6 months and/or after the recruitment of 75…read more →

Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing agreement signed for US Income growth and operating costs under control. Paris, April 15, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products today…read more →